Cytosorbents CORP 8-K filings

CytoSorbents Corporation's Q2 2026 update details revenue of $9.6 million, improved gross margins to 73%, and a reduced operating cash burn, with a strategic focus on achieving cash flow breakeven in the second half of 2026.

CytoSorbents Corporation announced its second quarter 2026 financial results, reporting flat revenue but improved gross margins and reduced operating losses, while outlining four key value drivers for future growth.

CytoSorbents Corporation received a notice from Nasdaq indicating non-compliance with minimum market value requirements, with 180 days to regain compliance.

CytoSorbents has scheduled two August 2026 FDA pre-submission meetings to advance its DrugSorb-ATR regulatory strategy.

CytoSorbents Corporation announced its first quarter 2026 financial results, showing a slight revenue increase but a wider net loss, while also providing updates on its DrugSorb-ATR regulatory pathway.

CytoSorbents Corporation announced its full year and fourth quarter 2025 financial results, showing modest revenue growth, improved GAAP net loss, but worsening adjusted net loss, alongside strategic restructuring and ongoing FDA discussions for DrugSorb-ATR.

CytoSorbents Corporation announced third quarter 2025 financial results, reporting 10% revenue growth, an amended credit agreement, and a workforce reduction plan aimed at achieving cash-flow breakeven by Q1 2026.

CytoSorbents Corporation received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, risking its listing.

CytoSorbents Corporation announced a regulatory update for DrugSorb-ATR, outlining a new expedited path with the FDA for market authorization after an appeal decision.

CytoSorbents Corporation announced the FDA upheld its De Novo denial for DrugSorb-ATR, citing a need for more information, but proposed a potential path forward for market authorization.

CytoSorbents Corporation reported a 9% revenue increase in Q2 2025, driven by strong German sales, but faces ongoing regulatory challenges for its DrugSorb-ATR device in the U.S. and Canada.

CytoSorbents Corporation highlights new studies demonstrating the vital and evolving role of its CytoSorb therapy in treating sepsis and septic shock, while facing regulatory denials for its DrugSorb-ATR device.

CytoSorbents Corporation announced regulatory setbacks for its DrugSorb-ATR device in both the U.S. and Canada, with the FDA scheduling an appeal hearing and Health Canada issuing a Notice of Refusal, though the company remains confident in its appeal processes.

CytoSorbents Corporation has filed an administrative appeal with the U.S. FDA regarding the denial of its De Novo Request for the DrugSorb-ATR device, aiming to resolve deficiencies and secure U.S. commercialization.

CytoSorbents Corporation announced that all proposals at its 2025 Annual Meeting of Stockholders, including the election of five directors, advisory approval of executive compensation, and ratification of its independent auditor, were approved.

CytoSorbents Corporation announced that its Series B Right Warrants expired worthless as the common stock's volume-weighted average price fell below the $2.00 minimum required price.

CytoSorbents announced its Q1 2025 financial results, highlighting a slight revenue decrease but improved operating loss and progress in strategic initiatives.

CytoSorbents Corporation received a denial letter from the FDA regarding its De Novo Request for DrugSorb-ATR, a device designed to reduce bleeding in coronary artery bypass grafting (CABG) patients.

CytoSorbents Corporation appoints Melanie Grossman as Vice President and Corporate Controller and grants her stock awards as an inducement.

CytoSorbents Corporation has appointed Thomas Shannon as Vice President of Marketing for North America to lead the marketing strategy for DrugSorb-ATR, pending regulatory approval.

CytoSorbents Corporation has extended the expiration date of its Series B Right Warrants from April 10, 2025, to June 10, 2025.

CytoSorbents announces a 25% increase in Q4 product revenue and expects regulatory decisions for DrugSorb-ATR in 2025.

CytoSorbents Corporation announced that it will restate its previously issued financial statements for the year ended December 31, 2023, and interim periods in 2023 and 2024 due to misstatements in inventory and stock-based compensation.

CytoSorbents Corporation announced a rescheduled earnings call for Q4 and full-year 2024, while reaffirming previously disclosed preliminary financial expectations and progress on DrugSorb-ATR regulatory submissions.

CytoSorbents Corp. announces a delay in its earnings release due to the passing of its Vice President and Corporate Controller, while reaffirming preliminary financial expectations for Q4 and full-year 2024.

CytoSorbents Corporation received $1.6 million in gross proceeds from the exercise of Series A Right Warrants, further bolstering its financial position.

CytoSorbents successfully closed its rights offering, raising $6.25 million and unlocking $5 million in restricted cash, significantly improving its financial position.

CytoSorbents Corporation has announced the opening of a new regional sales subsidiary in Dubai, United Arab Emirates, to expand its presence in the Middle East and Africa.

CytoSorbents reported preliminary unaudited fourth quarter and full-year 2024 results, highlighting significant revenue growth and improved gross margins.

CytoSorbents Corporation has announced the start of its rights offering, allowing eligible stockholders to purchase additional shares and warrants.